1. Introduction {#sec1-antibiotics-09-00389}
===============

The discovery of antibiotics remains one of the most important recent scientific advances in human health as it has increased the life expectancy of the population. However, the proportion of infections caused by resistant bacteria and by those with new patterns of resistance has been increasing for some years \[[@B1-antibiotics-09-00389],[@B2-antibiotics-09-00389]\]. It is estimated that more than 70% of pathogenic bacteria are resistant to at least one antibiotic \[[@B3-antibiotics-09-00389]\]. The use of antibiotics, especially broad-spectrum antibiotics, is the most important modifiable risk factor for the spread of resistance \[[@B1-antibiotics-09-00389],[@B4-antibiotics-09-00389],[@B5-antibiotics-09-00389]\]. Other related factors include the excessive use of antibiotics in agriculture, their misuse in veterinary medicine, their inadequate prescription in human medicine, growing globalization, and drug counterfeiting \[[@B3-antibiotics-09-00389],[@B6-antibiotics-09-00389]\].

Infections caused by resistant microorganisms are associated with an increased risk of morbidity, complications, mortality, health services use, and increased costs \[[@B3-antibiotics-09-00389],[@B7-antibiotics-09-00389],[@B8-antibiotics-09-00389]\]. Infectious diseases are currently the second leading cause of death worldwide, the third in developed countries and the fourth in the United States \[[@B9-antibiotics-09-00389]\]. It is estimated that worldwide, 17 million people die each year from bacterial infections \[[@B9-antibiotics-09-00389]\]. In the United States, approximately 2 million people contract antibiotic-resistant bacterial infections each year, and 23,000 of them die as a result of these infections \[[@B9-antibiotics-09-00389]\]. In the United States and in European countries, 67.9% of the total disability-adjusted life year (DALY) per 100,000 were due to infections caused by four antibiotic-resistant bacteria: *E. coli* resistant to third-generation cephalosporins, Methicillin-resistant *S. aureus*, carbapenem-resistant *P. aeruginosa*, and third-generation cephalosporin-resistant *K. pneumoniae* \[[@B10-antibiotics-09-00389]\].

Proper prescription of antibiotics is essential to reduce resistance \[[@B1-antibiotics-09-00389]\] and ensure the long-term availability of effective treatments for bacterial infections \[[@B7-antibiotics-09-00389]\], and it is currently a public health priority \[[@B11-antibiotics-09-00389],[@B12-antibiotics-09-00389]\]. However, despite the growth of antimicrobial resistance, the approval of new antibiotics has decreased by 90% in recent years in the United States due to the high cost of developing these drugs and the rapid evolution of resistance \[[@B3-antibiotics-09-00389]\]. It is evident that there is currently an urgent need to develop new antibiotics to avoid returning to the pre-antibiotic era \[[@B9-antibiotics-09-00389]\].

However, it is unlikely that this problem can be solved solely by the development of new antimicrobial drugs because the threat of resistance will always accompany any new drugs introduced for clinical use. Therefore, it is essential to implement rational drug use programs, improve targeted antibiotic therapy, and establish preventive measures and faster diagnostic tools, among other strategies, as these are the only ways to preserve antibiotics for future generations and ensure a healthy future for the world population \[[@B2-antibiotics-09-00389]\].

The World Health Organization (WHO) developed an instrument that seeks to improve the quality of antibiotic prescriptions to decrease the spread of resistant microorganisms and reduce adverse reactions and costs. The AWaRe tool classifies antibiotics into three groups: Access (for example: penicillins, beta lactams with beta-lactamase inhibitors, first-generation cephalosporins, tetracyclines, aminoglycosides, lincosamides, among others), Watch (for example: second, third or fourth generation cephalosporins, macrolides, carbapenems, fluoroquinolones, among others) and Reserve (for example: monobactams, fifth generation cephalosporins, polymyxins, glycopeptides, among others) \[[@B13-antibiotics-09-00389],[@B14-antibiotics-09-00389],[@B15-antibiotics-09-00389]\]. Antibiotics in the Access group are those that should initially be used for the most common and severe infections, are narrow spectrum, are and less expensive; antibiotics under surveillance (Watch) should be used in moderation due to the relatively high risk of resistant strains; and Reserve antibiotics are to be used for the treatment of infections by microorganisms resistant to multiple antibiotics \[[@B13-antibiotics-09-00389],[@B14-antibiotics-09-00389],[@B15-antibiotics-09-00389]\]. However, some limitations of the AWaRe tool must be recognized, including that not all classes of antibiotics are categorized, requires local adaptation and updates over time \[[@B13-antibiotics-09-00389]\]. The objective of the WHO is to increase the proportion of global consumption of antibiotics in the Access group by at least 60% and reduce the use of antibiotics in the Watch and Reserve groups, which are associated with an increased risk of resistance \[[@B13-antibiotics-09-00389],[@B14-antibiotics-09-00389]\]. Therefore, the tool could help to estimate the use of broad and narrow spectrum antibiotics, which facilitates the monitoring and optimization of their use \[[@B13-antibiotics-09-00389]\].

This becomes even more important, when it has been established that the general consumption of antibiotics increased 39% between the years 2000 to 2015, where most of the dispensations occurred in primary care centers \[[@B16-antibiotics-09-00389]\]. Differences in antibiotic prescription habits between countries have been established \[[@B17-antibiotics-09-00389],[@B18-antibiotics-09-00389]\], also between different geographical regions of given country \[[@B19-antibiotics-09-00389]\], and some studies have established differences between rural and urban areas \[[@B20-antibiotics-09-00389],[@B21-antibiotics-09-00389]\], while others have not been able to explore it \[[@B16-antibiotics-09-00389]\].

There is substantially less information on the patterns of antibiotic resistance in patients in the community than in hospitalized patients, on whom clinical practice recommendations are based \[[@B7-antibiotics-09-00389],[@B11-antibiotics-09-00389]\], and the behavior of prescription habits among large cities compared to those with fewer inhabitants is unknown. Therefore, we sought to compare the patterns of antibiotics prescriptions for outpatients between cities and municipalities in Colombia.

2. Results {#sec2-antibiotics-09-00389}
==========

A total of 182,397 people distributed throughout 187 different capital cities or municipalities who were prescribed an antibiotic were identified. Of these, 60.9% (*n* = 110,998) were women. The mean age was 37.1 ± 23.0 years (range: 0.08--108.75 years), with the following disbursement across age groups: \<18 years (*n* = 42,129; 23.1%), 18--49 years (*n* = 83,726; 45.9%), 50--64 years (*n* = 31,293; 17.1%), 65--79 years (*n* = 18,918; 10.4%) and ≥ 80 years (*n* = 6331; 3.5%). A total of 60.5% (*n* = 110,327) resided in capital cities, and most of them were in the Caribbean Region (*n* = 91,290; 50.1%), followed by the Bogotá--Cundinamarca Region (*n* = 45,476; 24.9%), Central Region (*n* = 20,752; 11.4%), Pacific Region (*n* = 18,928; 10.3%), Eastern Region (*n* = 5079; 2.8%), and Amazon--Orinoco Region (*n* = 872; 0.5%).

A total of 37 different antibiotics were prescribed; 90.2% (*n* = 164,447) of the patients received a single antimicrobial, while 8.8% (*n* = 16,049) received two, and 1.0% (*n* = 1901) received three or more. A total of 93.5% (*n* = 170,619) of the patients were given antibiotics to be used orally, with tablets or capsules being the most frequently prescribed pharmaceutical dosage form (*n* = 149,660; 82.1%) ([Table 1](#antibiotics-09-00389-t001){ref-type="table"}). The most commonly used groups of antibiotics were penicillins, followed by cephalosporins and fluoroquinolones ([Table 1](#antibiotics-09-00389-t001){ref-type="table"}). The most frequently prescribed antibiotic was amoxicillin, followed by cephalexin and nitrofurantoin ([Table 2](#antibiotics-09-00389-t002){ref-type="table"}). In terms of the AWaRe classification, 86.4% of the patients (*n* = 157,558) were prescribed Access antibiotics, 17.0% (*n* = 30,936) received Watch antibiotics, and 0.1% (*n* = 188) were prescribed Reserve antibiotics.

A total of 28.7% (*n* = 52,324) of all patients had some chronic pathology ([Table 1](#antibiotics-09-00389-t001){ref-type="table"}). Of these, 89.3% (*n* = 46,754) had one to two pathologies, 9.5% (*n* = 4964) had three to four pathologies, and 1.2% (*n* = 606) had five or more pathologies. These comorbidities predominated in individuals aged 65 years or older (*n* = 17,093/25,107; 68.1%). The 10 most common comorbidities were arterial hypertension (13.5%; *n* = 24,669), diabetes (8421; 4.6%), hypothyroidism (4469; 2.5%), chronic gastritis (3174; 1.7%), dyslipidemia (2707, 1.5%), acne (2691; 1.5%), benign prostatic hyperplasia (2246; 1.2%), cancer (2026; 1.1%), irritable colon (1903; 1.0%), and osteoarthritis (1832; 1.0%).

2.1. Comparison between Capital Cities and Municipalities {#sec2dot1-antibiotics-09-00389}
---------------------------------------------------------

Differences were found between capital cities and municipalities. In cities, it was more common to find prescriptions of a single antibiotic, tablet or capsule pharmaceutical dosage forms, penicillins, urinary antiseptics, tetracyclines, rifamycins and lincosamides, while in municipalities, it was more common to prescribe two or more antibiotics, injectable pharmaceutical dosage forms, cephalosporins, fluoroquinolones, macrolides, and aminoglycosides ([Table 1](#antibiotics-09-00389-t001){ref-type="table"}). Amoxicillin was the most commonly used antibiotic in cities, while ciprofloxacin was the most commonly used antibiotic in municipalities, and there was no significant difference regarding cephalexin. The Access and Reserve groups of antibiotics were prescribed more frequently in cities, while the Watch group predominated in municipalities ([Table 2](#antibiotics-09-00389-t002){ref-type="table"}).

2.2. Comparison among Age Groups {#sec2dot2-antibiotics-09-00389}
--------------------------------

In each of the age groups, women and residents of cities represented the majority. For those under 18 years of age, the prescription of two or more antibiotics was less likely than for the other age groups. The pharmaceutical dosage forms of tablets or capsules predominated among those aged 18 and older, while powder to reconstitute to an oral solution was more frequently prescribed for those under 18 years of age. Penicillins and cephalosporins were prescribed more frequently to children under 18 years of age, while the prescription of fluoroquinolones and urinary antiseptics increased with advancing age and was most common for those older than 65 years. The prescription of tetracyclines showed a peak among patients between the ages 18 and 49 years, while prescriptions for macrolides, sulfonamides and aminoglycosides did not vary greatly among the different age groups. The prescription of antibiotics classified as Access decreased with patient age (*p* \< 0.001), while the prescription of Watch and Reserve antibiotics increased with patient age (*p* \< 0.001) ([Table 3](#antibiotics-09-00389-t003){ref-type="table"}).

2.3. Comparison among Geographic Regions {#sec2dot3-antibiotics-09-00389}
----------------------------------------

The prescription of two or more antibiotics was found most frequently in the Caribbean Region. Penicillins, followed by cephalosporins, were the most commonly prescribed antibiotic groups in all regions of the country. In the Caribbean Region, the prescription of fluoroquinolones, macrolides and aminoglycosides was more common than in the other geographic regions, while tetracyclines were most often prescribed in Bogotá--Cundinamarca, and urinary antiseptics were most often prescribed in the Central and Pacific regions. The prescription of Access antibiotics predominated in the Bogotá--Cundinamarca Region, while the prescription of Watch antibiotics predominated in the Pacific and Caribbean regions ([Table 4](#antibiotics-09-00389-t004){ref-type="table"}).

2.4. Multivariate Analysis {#sec2dot4-antibiotics-09-00389}
--------------------------

A binary logistic regression model was conducted using the prescription of antibiotics classified as Watch or Reserve (yes/no) as a dependent variable. The multivariate analysis found that prescriptions written in municipalities; the presence of one or more comorbidities; and the presence of urinary, respiratory or gastrointestinal pathologies increased the probability of receiving antibiotics classified as Watch and/or Reserve, while residing in the Bogotá--Cundinamarca, Central or Eastern regions and having dermatological, rheumatological, cardiovascular or neurological pathologies reduced this risk. Interaction terms were analyzed. There was an interaction between age and male sex; with higher probability of receiving Watch/Reserve antibiotics with increasing age ([Table 5](#antibiotics-09-00389-t005){ref-type="table"}). Other interaction terms were tested but none was statistically significative (positive nor negative effects).

3. Discussion {#sec3-antibiotics-09-00389}
=============

The patterns of antibiotic prescription for outpatients of any age and sex were evaluated for nearly one-sixth of the population of Colombia to characterize the differences and similarities in the dispensing of these drugs according to geographic region, capital city or municipality and age group and the variables associated with the use of antibiotics classified as Watch or Reserve. In general, antibiotics were more often prescribed for women, a finding that has also been reported in the United States \[[@B1-antibiotics-09-00389],[@B5-antibiotics-09-00389]\], Europe \[[@B17-antibiotics-09-00389],[@B22-antibiotics-09-00389],[@B23-antibiotics-09-00389]\] and Africa \[[@B24-antibiotics-09-00389]\]. The reason for this is that infectious diseases vary between men and women due to factors related to genetics, biology, and behavioral differences \[[@B25-antibiotics-09-00389]\].

Penicillins were the most commonly used pharmacological group (38.6%), which is consistent with the findings of Goossens et al. in a multicenter study conducted in 28 countries in Europe and North America (38.9--45.7%) \[[@B26-antibiotics-09-00389]\] and those of Elseviers et al. in 24 European countries (32.0--63.0%) \[[@B27-antibiotics-09-00389]\]. Different studies have documented that in the United States and Malaysia, the use of penicillins predominated, but at a lower proportion (23.0% and 30.7%, respectively) \[[@B1-antibiotics-09-00389],[@B12-antibiotics-09-00389]\]; this differs from the results of other American studies in which the most commonly prescribed antibiotics were fluoroquinolones (22.0--25.0%) \[[@B5-antibiotics-09-00389],[@B11-antibiotics-09-00389]\], and with a study indicating that in Greece, the use of macrolides was more frequent (29.9%) \[[@B4-antibiotics-09-00389]\].

Amoxicillin was the most commonly prescribed antibiotic (28.1%) in the present study, a finding consistent with results for countries in North America, Europe, Asia, and Africa (20.8--22.5%) \[[@B12-antibiotics-09-00389],[@B24-antibiotics-09-00389],[@B26-antibiotics-09-00389]\] and with what was documented between 2006 and 2007 in Colombia (27.8%--29.7%) \[[@B28-antibiotics-09-00389]\]. In the United States and Greece, the use of azithromycin (14.0--54.1%) \[[@B1-antibiotics-09-00389],[@B5-antibiotics-09-00389],[@B29-antibiotics-09-00389]\] and clarithromycin (19.8%) \[[@B4-antibiotics-09-00389]\], respectively, predominated. These variations in the prescription of antibiotics may be due to the existing epidemiological differences between countries in terms of the type and frequency of bacterial infections, the etiological agents involved, and their resistance patterns; variations may also be due to differences in clinical practice guidelines, which in some cases do not yield the same recommendations, as well as the marketing strategies of the pharmaceutical industry and the characteristics of each country's health systems and accessibility to healthcare services.

Many studies have shown that the frequency of use and prescription patterns of antibiotics varies according to the geographical area of each country \[[@B1-antibiotics-09-00389],[@B5-antibiotics-09-00389],[@B17-antibiotics-09-00389],[@B22-antibiotics-09-00389],[@B23-antibiotics-09-00389],[@B30-antibiotics-09-00389]\], a finding that was also evidenced in this analysis. No published studies comparing antibiotics use between the capital cities and municipalities of any country were found. However, in the Netherlands, de Jong et al. compared the use of antibiotics in patients who lived in rural areas with that of patients who lived in urban areas and found that the prevalence of antibiotic prescriptions was higher in rural areas (23.6% versus 20.2%, *p* \< 0.001). In addition, the most commonly used antibiotic groups were penicillins and tetracyclines, which predominated in rural areas \[[@B20-antibiotics-09-00389]\]. A study carried out in a region of Vietnam, for 3 consecutive days, evaluated the sales of medicines from 30 private pharmacies, 15 rural and 15 urban, finding that antibiotics represented 30% and 24% (*p* = 0.002) of dispensations from rural and urban pharmacies, with amoxicillin being the best-selling antibiotic (27% vs. 13%, *p* \< 0.0001) \[[@B31-antibiotics-09-00389]\]. In the United States, rural prescribers were more likely to formulate large amounts of antibiotics \[[@B32-antibiotics-09-00389]\]. However, in a study conducted in Italy, urban municipalities were eight times more likely to have high prevalence rates of antibiotic use compared to rural municipalities (adjusted OR: 8.62; 95% CI: 4.06--18.30, *p* \< 0.001) \[[@B21-antibiotics-09-00389]\] and also in an investigation carried out in Sweden, the prescription of antibiotics was higher in urban areas \[[@B19-antibiotics-09-00389]\]. In our study, significant differences were found in the prescription of some antibiotics, highlighting the use of fluoroquinolones, macrolides, aminoglycosides, and cephalosporins in the population residing in municipalities and penicillins and tetracyclines among those residing in cities. Among the factors that may influence these differences are the habits of prescribers and their degree of continuing education, as well as the prevalence of infectious pathologies, comorbidities, socioeconomic, cultural factors, and the educational level of patients, as well as the absence of local pharmacovigilance programs. Note that fluoroquinolones, macrolides and many cephalosporins belong to the Watch antimicrobial group.

In England, the majority of prescribed antibiotics were classified as Access (68.7%), followed by Watch (18.4%) and Reserve (0.4%) \[[@B33-antibiotics-09-00389]\]; and in 70 high- and middle-income countries, the median rate of prescription of Access antibiotics was 76.3% (27.0--94.4%), compared with 12.3% (3.3--54.0%) for Watch antibiotics and 1.0% for Reserve antibiotics \[[@B34-antibiotics-09-00389]\]. The Watch/Access ratio of these studies is consistent with that found in the present analysis of a sample of 20% of the prescriptions in Colombia: Access antibiotics were the most frequently prescribed group in the different geographical regions throughout the country, showing compliance with the WHO's goal of using these antibiotics in a proportion greater than 60% in order to reduce microorganism resistance and achieve better therapeutic results \[[@B35-antibiotics-09-00389]\].

Watch antibiotics have not been sufficiently characterized in epidemiological studies because this classification was first proposed by the WHO in 2017. In our analysis, this group was mainly represented by fluoroquinolones and macrolides, and the factors that were associated with increased use of this group of antibiotics were male sex, older age and number of comorbidities, probably because these drugs are indicated for prostatitis, sexually-transmitted infections, urinary tract infections, and upper and lower respiratory tract infections \[[@B36-antibiotics-09-00389]\]. However, in this study, the specific clinical indications for the prescribed antibiotics could not be determined. Ciprofloxacin stood out as one of the most prescribed Watch antibiotics in this sample of Colombian prescriptions. In different studies, ciprofloxacin was used by 5.7--20.9% \[[@B1-antibiotics-09-00389],[@B4-antibiotics-09-00389],[@B5-antibiotics-09-00389],[@B12-antibiotics-09-00389],[@B24-antibiotics-09-00389]\] of patients, and in Colombia between 2006--2007, it was used by 8.6% \[[@B28-antibiotics-09-00389]\], slightly lower than its current rate of use in the country (9.2%). Its use, like that of Watch antibiotics in general, predominated in municipalities.

Some limitations in the interpretation of the results are recognized. There was no access to medical records to identify the clinical indications for the prescription of antibiotics, nor could it be established whether the antibiotics were taken as recommended, including whether they were taken for the minimum time. Likewise, on medical forms, the ICD-10 code corresponding to the infectious disease is not always recorded; thus, the quality of the prescriptions could not be determined, and information about antibiotics purchased outside the health system is unknown.

4. Materials and Methods {#sec4-antibiotics-09-00389}
========================

This was a cross-sectional study of the prescription of antibiotics for outpatient use. It compared antibiotics use between capital cities and municipalities in a group of Colombian patients from a population-based drug-dispensing database that collects information on approximately 8.5 million persons affiliated with the Colombian Health System and six insurers. The population covered by the database corresponds to 30.0% of the active population affiliated with the contributory regime and 6.0% with the subsidized regime, which corresponds to 16.3% of the Colombian population.

Patients of any age and sex who were treated at outpatient clinics and received antibiotics for outpatient use between January 1 and 31, 2020 were selected. A database was designed to collect the following groups of variables:Sociodemographic: Sex, age, insurance company, and place of dispensation (the term city was used to refer to all the capitals of Colombian departments (regions), and the term municipality was used for all other populations with fewer inhabitants). Capital city and municipality of dispensation: See annex 1Geographic areas: The region of residence was categorized by department according to the regions of Colombia and considering the classification of the National Administrative Department of Statistics (Departamento Administrativo Nacional de Estadística---DANE) of Colombia as follows:Caribbean Region: Atlántico, Bolívar, Cesar, Córdoba, La Guajira, Magdalena, Sucre, San Andrés, Providencia, and Santa Catalina.Central Region: Antioquia, Caldas, Quindío, Risaralda, Caquetá, Huila, Tolima.Bogotá--Cundinamarca Region.Eastern Region: Boyacá, Meta, Norte de Santander, Santander, Arauca, Casanare.Pacific Region: Cauca, Chocó, Nariño, Valle del Cauca.Amazon--Orinoco Region: Amazonas, Guaviare, Guainía, Vaupés, Vichada, Putumayo.Chronic comorbidities: Identified from the main and secondary diagnoses reported using ICD-10 codes in the database between October 1, 2019, and January 31, 2020. Chronic comorbidities were grouped into four categories: no comorbidities and one, two and three or more pathologies. The following groups of diseases were considered: Cardiovascular: High blood pressure, ischemic heart disease, tachyarrhythmias, heart failure, peripheral arterial disease.Endocrine: Diabetes, hypothyroidism, dyslipidemia, obesity, hyperthyroidism.Rheumatological: Osteoarthrosis, rheumatoid arthritis, osteoporosis, fibromyalgia, systemic lupus erythematosus, systemic sclerosis, ankylosing spondylitis.Renal: Chronic kidney disease.Psychiatric: Depression, anxiety, bipolar affective disorder, sleep disorders, psychosis.Neurological: Peripheral neuropathies, chronic pain, dementia, migraine, epilepsy, Parkinson's disease, stroke, mental retardation.Digestive: Chronic gastritis, gastroesophageal reflux, constipation, cirrhosis, peptic ulcer, hepatitis, irritable colon.Respiratory: Chronic obstructive pulmonary disease, asthma.Urinary: Benign prostatic hyperplasia, urinary incontinence/overactive bladderSkin: Acne, psoriasis.Antibiotic groups according to the AWaRe classification (13) (see [Table 6](#antibiotics-09-00389-t006){ref-type="table"}):Pharmaceutical dosage forms: Tablet, capsule, powder for reconstitution to oral solution, suspension, injectable solution, powder for inhalation.Number of antibiotics per patient: Grouped into three categories: One antibiotic, two antibiotics and three or more antibiotics received during the month of January.

The protocol was approved by the Bioethics Committee of Universidad Tecnológica de Pereira in the category of risk-free research (approval number: 05-090320). The ethical principles established by the Declaration of Helsinki were respected.

The data were analyzed with the statistical package SPSS Statistics, version 26.0 for Windows (IBM, USA). A descriptive analysis was performed with frequencies and proportions for the qualitative variables and measures of central tendency and dispersion for the quantitative variables. Quantitative variables were compared using Student's t-test or ANOVA; categorical variables (i.e., age groups according to AWaRe classification) were compared using the X2 test. The Benjamini--Hochberg method was used to adjust for multiple hypotheses. An exploratory binary logistic regression model was fitted using the prescription of antibiotics classified as Watch or Reserve (yes/no). Sex, age groups and variables that were significantly associated in the bivariate analyses were used as covariates. Interaction terms and multicollinearity were also assessed (Variance inflation factor---VIF \<10 as limit). The level of statistical significance adopted was *p* \< 0.05.

5. Conclusions {#sec5-antibiotics-09-00389}
==============

The study results indicate that there are differences in the patterns of antibiotic prescription between capital cities and more rural municipalities; in particular, there is a greater proportion of Watch antibiotic use in municipalities than in cities, and there are differences in the prescription of penicillins, cephalosporins, fluoroquinolones, and macrolides. In general, the goals established by the WHO to reduce resistance to antimicrobials are being met, but it is necessary to implement continuing medical education measures to promote more homogeneous prescription patterns between cities and municipalities in different regions of the country. Studies of the use of antibiotics at the patient level in areas that prescribe a higher proportion of Watch antibiotics could provide data on the reasons for their use and whether it complies with treatment guidelines.
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antibiotics-09-00389-t001_Table 1

###### 

Comparison of sociodemographic, clinical and pharmacological characteristics of the patients included in the sample according to the place their live, Capital cities or small Municipalities (*p* values calculated by Chi-square/Fisher's exact test, and adjusted using the Benjamini--Hochberg method)).

  Variables                                 Total           Capital Cities   Municipalities   *p*                       
  ----------------------------------------- --------------- ---------------- ---------------- --------- -------- ------ ---------
  Women                                     110,998         60.9             67,043           60.8      43,955   61,0   0.522
  Men                                       71,399          39.1             43,284           39.2      28,115   39.0   0.522
  Age (mean; SD)                            37.06 ± 23.04   38.36 ± 22.35    35.06 ± 23.91    \<0.001                   
  Chronic comorbidities                     52,324          28.7             37,866           34.3      14,458   20.1   \<0.001
  Cardiovascular                            25,421          13.9             18,398           16.7      7,023    9.7    \<0.001
  Endocrine                                 16,050          8.8              11,805           10.7      4245     5.9    \<0.001
  Gastrointestinal                          6910            3.8              5396             4.9       1514     2.1    \<0.001
  Neurological                              5272            2.9              3995             3.6       1277     1.8    \<0.001
  Urinary                                   3907            2.1              2646             2.4       1261     1.7    \<0.001
  Psychiatric                               3639            2.0              2693             2.4       946      1.3    \<0.001
  Rheumatological                           3398            1.9              2488             2.3       910      1.3    \<0.001
  Respiratory                               3106            1.7              2208             2.0       898      1.2    \<0.001
  Kidney                                    1495            0.8              889              0.8       606      0.8    0.522
  Number of antibiotics per patient         \-              \-               \-               \-        \-       \-     \-
  1                                         164,447         90.2             100,639          91.2      63,808   88.5   \<0.001
  2                                         16,049          8.8              8772             8.0       7277     10.1   \<0.001
  3 or more                                 1901            1.0              916              0.8       985      1.4    \<0.001
  Pharmaceutical forms                      \-              \-               \-               \-        \-       \-     \-
  Tablet or capsule                         149,660         82.1             94,075           85.3      55,585   77.1   \<0.001
  Powder to reconstitute to oral solution   25,980          14.2             12,566           11.4      13,414   18.6   \<0.001
  Injectable                                11,778          6.5              5886             5.3       5892     8.2    \<0.001
  Suspension                                2328            1.3              989              0.9       1339     1.9    \<0.001
  Inhalation                                14              0.0              12               0.0       2        0.0    0.428
  Antibiotic groups                         \-              \-               \-               \-        \-       \-     \-
  Penicillins                               70,380          38.6             43,668           39.6      26,712   37.1   \<0.001
  With beta-lactamase inhibitors            2068            1.1              1486             1.3       582      0.8    \<0.001
  Cephalosporins                            55,013          30.2             32,182           29.2      22,831   31.7   \<0.001
  Fluoroquinolones                          19,813          10.9             10,190           9.2       9623     13.4   \<0.001
  Urinary antipseptics                      14,839          8.1              9639             8.7       5200     7.2    \<0.001
  Tetracyclines                             11,970          6.6              9085             8.2       2885     4.0    \<0.001
  Macrolides                                9778            5.4              5269             4.8       4509     6.3    \<0.001
  Sulfonamides                              8731            4.8              5338             4.8       3393     4.7    0.522
  Aminoglycosides                           6596            3.6              2436             2.2       4160     5.8    \<0.001
  Rifamycins                                418             0.2              382              0.3       36       0.0    \<0.001
  Lincosamides                              84              0.0              75               0.0       9        0.0    \<0.001
  Oxazolidinones                            11              0.0              9                0.0       2        0.0    0.522
  Phenicols                                 6               0.0              2                0.0       4        0.0    0.522
  Glycopeptides                             2               0.0              2                0.0       0        0.0    0.522

antibiotics-09-00389-t002_Table 2

###### 

Comparison of the antibiotics prescribed in the Capital cities and the small Municipalities, according to the AWaRe classification (*p* values calculated by Chi-square/Fisher's exact test, and adjusted using the Benjamini--Hochberg method).

  Antibiotics                     Total     Capital Cities   Municipalities   *p*                    
  ------------------------------- --------- ---------------- ---------------- ------ -------- ------ ---------
  **Access**                      157,558   86.4             96,942           87.9   60,616   84.1   \<0.001
  Amoxicillin                     51,326    28.1             32,825           29.8   18,501   25.7   \<0.001
  Cephalexin                      47,256    25.9             28,501           25.8   18,755   26.0   0.744
  Nitrofurantoin                  14,674    8.0              9493             8.6    5181     7.2    \<0.001
  Dicloxacillin                   11,675    6.4              6526             5.9    5149     7.1    \<0.001
  Doxycycline                     11,281    6.2              8526             7.7    2755     3.8    \<0.001
  Trimethoprim sulfamethoxazole   8731      4.8              5338             4.8    3393     4.7    0.744
  Cephradine                      6328      3.5              2558             2.3    3770     5.2    \<0.001
  Gentamicin                      5803      3.2              2068             1.9    3735     5.2    \<0.001
  Benzathine penicillin G         3732      2.0              2365             2.1    1367     1.9    0.003
  Ampicillin                      2513      1.4              965              0.9    1548     2.1    \<0.001
  Amoxicillin + Clavulanate       1436      0.8              984              0.9    452      0.6    \<0.001
  Amikacin                        787       0.4              360              0.3    427      0.6    \<0.001
  Tetracycline                    689       0.4              559              0.5    130      0.2    \<0.001
  Ampicillin + sulbactam          631       0.3              502              0.5    129      0.2    \<0.001
  Clindamycin                     84        0.0              75               0.1    9        0.0    \<0.001
  Moxifloxacin                    69        0.0              63               0.1    6        0.0    \<0.001
  Phenoxymethyl penicillin        64        0.0              50               0.0    14       0.0    0.035
  Tobramicin                      14        0.0              12               0.0    2        0.0    0.471
  Chloramphenicol                 6         0.0              2                0.0    4        0.0    0.744
  Limecyclin                      6         0.0              6                0.0    0        0.0    0.526
  Minocyclin                      6         0.0              6                0.0    0        0.0    0.526
  Amoxicillin + Sulbactam         5         0.0              4                0.0    1        0.0    0.744
  Cefadroxil                      2         0.0              1                0.0    1        0.0    0.999
  **Watch**                       30,936    17.0             16,503           15.0   14,433   20.0   \<0.001
  Ciprofloxacin                   16,866    9.2              8636             7.8    8230     11.4   \<0.001
  Azithromycin                    4015      2.2              1504             1.4    2511     3.5    \<0.001
  Clarithromycin                  2852      1.6              1879             1.7    973      1.4    \<0.001
  Erythromycin                    2707      1.5              1752             1.6    955      1.3    \<0.001
  Norfloxacin                     2649      1.5              1301             1.2    1348     1.9    \<0.001
  Ceftriaxone                     1560      0.9              1145             1.0    415      0.6    \<0.001
  Levofloxacin                    289       0.2              208              0.2    81       0.1    \<0.001
  Spiramycin                      232       0.1              147              0.1    85       0.1    0.999
  Cefuroxime                      103       0.1              91               0.1    12       0.0    \<0.001
  Cefpodoxime                     1         0.0              1                0.0    0        0.0    0.999
  Vancomycin                      2         0.0              2                0.0    0        0.0    0.999
  **Reserve**                     188       0.1              167              0.2    21       0.0    \<0.001
  Fosfomycin                      177       0.1              158              0.1    19       0.0    \<0.001
  Linezolid                       11        0.0              9                0.0    2        0.0    0.876
  **Others** (Rifaximin)          418       0.2              382              0.3    36       0.0    \<0.001
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###### 

Distribution of the antibiotic prescription in the study sample according to the age group.

  Variables                                 \<18 Years   18--49 Years   50--64 Years   65--79 Years   ≥80 Years                                 
  ----------------------------------------- ------------ -------------- -------------- -------------- ----------- ------ -------- ------ ------ ------
  Women                                     21,125       50.1           55,217         65.9           19,863      63.5   10,970   58.0   3823   60.4
  Men                                       21,004       49.9           28,509         34.1           11,430      36.5   7948     42.0   2508   39.6
  Prescription in capital city              21,271       50.5           53,774         64.2           19,657      62.8   11,805   62.4   3820   60.3
  Chronic comorbidities                     3808         9.0            16,382         19.6           14,951      47.8   12,507   66.1   4676   73.9
  Cardiovascular                            799          1.9            5261           6.3            7984        25.5   8234     43.5   3143   49.6
  Endocrines                                474          1.1            4560           5.4            5533        17.7   4249     22.5   1234   19.5
  Gastrointestinal                          429          1.0            2907           3.5            1987        6.3    1197     6.3    390    6.2
  Neurologic                                335          0.8            2119           2.5            1050        3.4    987      5.2    781    12.3
  Urinary                                   85           0.2            383            0.5            993         3.2    1500     7.9    946    14.9
  Psychiatric                               127          0.3            1284           1.5            1080        3.5    763      4.0    385    6.1
  Rheumatological                           29           0.1            527            0.6            1237        4.0    1196     6.3    409    6.5
  Respiratory                               692          1.6            454            0.5            514         1.6    895      4.7    551    8.7
  Kidney                                    10           0              93             0.1            226         0.7    633      3.3    533    8.4
  Number of antibiotics per patient         \-           \-             \-             \-             \-          \-     \-       \-     \-     \-
  1                                         39,357       93.4           74,597         89.1           27,892      89.1   16,922   89.4   5679   89.7
  2                                         2530         6.0            8158           9.7            3043        9.7    1747     9.2    571    9.0
  3 or more                                 242          0.6            971            1.2            358         1.1    249      1.3    81     1.3
  Pharmaceutical forms                      \-           \-             \-             \-             \-          \-     \-       \-     \-     \-
  Tablet or capsule                         14,084       33.4           80,542         96.2           30,455      97.3   18,463   97.6   6116   96.6
  Powder to reconstitute to oral solution   25,520       60.6           226            0.3            70          0.2    86       0.5    78     1.2
  Injectable                                1420         3.4            7075           8.5            1975        6.3    999      5.3    309    4.9
  Suspension                                2244         5.3            37             0.0            18          0.1    11       0.1    18     0.3
  Inhalation                                7            0.0            7              0.0            0           0.0    0        0.0    0      0.0
  Antibiotic groups                         \-           \-             \-             \-             \-          \-     \-       \-     \-     \-
  Penicillins                               20,142       47.8           31,122         37.2           11,556      36.9   5857     31.5   1603   25.3
  With beta-lactamase inhibitors            494          1.2            777            0.9            379         1.2    278      1.5    140    2.2
  Cephalosporins                            15,169       36.0           24,403         29.1           8425        26.9   5201     27.5   1815   28.7
  Fluoroquinolones                          625          1.5            9277           11.1           4994        16.0   3672     19.4   1245   19.7
  Urinary antiseptics                       563          1.3            7804           9.3            3081        9.8    2286     12.1   1105   17.5
  Tetracyclines                             2109         5.0            7606           9.1            1378        4.4    694      3.7    183    2.9
  Macrolides                                2470         5.9            4111           4.9            1754        5.6    1072     5.7    371    5.9
  Sulfonamides                              2224         5.3            3681           4.4            1558        5.0    920      4.9    348    5.5
  Aminoglycosides                           678          1.6            3638           4.3            1341        4.3    724      3.8    215    3.4
  Rifamycins                                8            0.0            95             0.1            123         0.4    153      0.8    39     0.6
  Lincosamides                              2            0.0            48             0.1            21          0.1    8        0.0    5      0.1
  Oxazolidinones                            0            0.0            5              0.0            3           0.0    2        0.0    1      0.0
  Phenicols                                 1            0.0            1              0.0            1           0.0    1        0.0    2      0.0
  Glycopeptides                             0            0.0            1              0.0            0           0.0    0        0.0    1      0.0
  AWaRe classification                      \-           \-             \-             \-             \-          \-     \-       \-     \-     \-
  Access                                    39,382       93.5           72,752         86.9           25,717      82.2   14,795   78.2   4911   77.6
  Watch                                     3255         7.7            14,350         17.1           6867        21.9   4817     25.5   1646   26.0
  Reserve                                   1            0.0            55             0.1            40          0.1    58       0.3    34     0.5
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###### 

Comparison of different sociodemographic and pharmacological variables of patients who had one or more antibiotic prescriptions according to the Colombian geographic regions.

  Variables                                 Caribbean Region   Bogota--Cundinamarca Region   Central Region   Pacific Region   Eastern Region   Amazonia--Orinoco Region                                       
  ----------------------------------------- ------------------ ----------------------------- ---------------- ---------------- ---------------- -------------------------- -------- ------ ------ ------ ----- -------
  Women                                     55,737             61.1                          28,028           61.6             12,458           60.0                       11,249   59.4   3020   59.5   506   58.0
  Men                                       35,553             38.9                          17,448           38.4             8294             40.0                       7679     40.6   2059   40.5   366   42.0
  Prescription in capital city              40,170             44.0                          39,439           86.7             15,554           75.0                       10,545   55.7   3747   73.8   872   100.0
  Chronic comorbidities                     15,464             16.9                          17,654           38.8             8752             42.2                       8444     44.6   1926   37.9   84    9.6
  Number of antibiotics per patient         \-                 \-                            \-               \-               \-               \-                         \-       \-     \-     \-     \-    \-
  1                                         80,727             88.4                          42,254           92.9             18,932           91.2                       17,037   90.0   4704   92.6   793   90.9
  2                                         9306               10.2                          2954             6.5              1643             7.9                        1737     9.2    341    6.7    68    7.8
  3 or more                                 1257               1.4                           268              0.6              177              0.9                        154      0.8    34     0.7    11    1.3
  Pharmaceutical forms                      \-                 \-                            \-               \-               \-               \-                         \-       \-     \-     \-     \-    \-
  Tablet or capsule                         68,773             75.3                          40,721           89.5             18,142           87.4                       17,040   90.0   4328   85.2   656   75.2
  Powder to reconstitute to oral solution   18,699             20.5                          3387             7.4              1871             9.0                        1228     6.5    625    12.3   170   19.5
  Injectable                                7343               8.0                           1850             4.1              1057             5.1                        1274     6.7    186    3.7    68    7.8
  Suspension                                1805               2.0                           203              0.4              154              0.7                        109      0.6    46     0.9    11    1.3
  Inhalation                                2                  0.0                           6                0.0              3                0.0                        3        0.0    0      0.0    0     0.0
  Antibiotic groups                         \-                 \-                            \-               \-               \-               \-                         \-       \-     \-     \-     \-    \-
  Penicillins                               31,685             34.7                          20,166           44.3             8697             41.9                       7323     38.7   2174   42.8   335   38.4
  With beta-lactamase inhibitors            1098               1.2                           410              0.9              216              1.0                        288      1.5    50     0.0    6     0.7
  Cephalosporins                            31,158             34.1                          11,536           25.4             5443             26.2                       5210     27.5   1342   26.4   324   37.2
  Fluoroquinolones                          11,896             13.0                          2980             6.6              1659             8.0                        2740     14.5   460    9.1    78    8.9
  Urinary antipseptics                      6450               7.1                           3960             8.7              2108             10.2                       1828     9.7    437    8.6    56    6.4
  Tetracyclines                             3816               4.2                           5082             11.2             1752             8.4                        924      4.9    361    7.1    35    4.0
  Macrolides                                5624               6.2                           1796             3.9              1107             5.3                        976      5.2    232    4.6    43    4.9
  Sulfonamides                              4589               5.0                           1843             4.1              1092             5.3                        900      4.8    272    5.4    35    4.0
  Aminoglycosides                           5304               5.8                           339              0.7              320              1.5                        497      2.6    95     1.9    41    4.7
  Rifamycins                                51                 0.1                           197              0.4              90               0.4                        71       0.4    8      0.2    1     0.1
  Lincosamides                              17                 0.0                           42               0.1              12               0.1                        11       0.1    2      0.0    0     0.0
  Oxazolidinones                            1                  0.0                           1                0.0              5                0.0                        4        0.0    0      0.0    0     0.0
  Phenicols                                 2                  0.0                           0                0.0              1                0.0                        3        0.0    0      0.0    0     0.0
  Glycopeptides                             0                  0.0                           2                0.0              0                0.0                        0        0.0    0      0.0    0     0.0
  AWaRe classification                      \-                 \-                            \-               \-               \-               \-                         \-       \-     \-     \-     \-    \-
  Access                                    77,022             84.4                          41,191           90.6             18,434           88.8                       15,658   82.7   4489   88.4   764   87.6
  Watch                                     17,981             19.7                          5192             11.4             2946             14.2                       3960     20.9   718    14.1   139   15.9
  Reserve                                   24                 0                             73               0.2              31               0.1                        53       0.3    6      0.1    1     0.1
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###### 

Multivariate analysis of the variables associated with the prescription of Watch and Reserve antibiotics in the study sample from Colombia, January, 2020.

  Variables                           *p* Value   OR          95% IC      
  ----------------------------------- ----------- ----------- ----------- -----------
  Men                                 0.001       0.888       0.827       0.954
  Age groups                                                              
  Age \<18 years                      \<0.001     Reference   Reference   Reference
  Age 18--49 years                    \<0.001     2.656       2.515       2.805
  Age 50--64 years                    \<0.001     3.464       3.256       3.684
  Age ≥65 years                       \<0.001     3.952       3.699       4.221
  Age groups by Men                                                       
  Age 18--49 years                    \<0.001     1.174       1.082       1.274
  Age 50--64 years                    0.001       1.161       1.059       1.272
  Age ≥65 years                       \<0.001     1.234       1.124       1.354
  Prescription in municipalities      \<0.001     1.269       1.235       1.304
  Caribbean region                    0.230       1.120       0.930       1.349
  Central region                      \<0.001     0.663       0.549       0.801
  Bogota-Cundinamarca region          \<0.001     0.547       0.453       0.659
  Eastern region                      0.001       0.700       0.573       0.857
  Pacific region                      0.365       0.916       0.759       1.106
  No chronic comorbidities            \<0.001     Reference   Reference   Reference
  One chronic comorbidity             \<0.001     1.142       1.078       1.210
  Two or more chronic comorbidities   \<0.001     1.282       1.151       1.429
  Cardiovascular pathologies          \<0.001     0.874       0.822       0.929
  Endocrine pathologies               0.199       0.962       0.903       1.025
  Gastrointestinal pathologies        \<0.001     1.320       1.227       1.420
  Neurological pathologies            \<0.001     0.844       0.777       0.916
  Dermatological pathologies          \<0.001     0.243       0.197       0.300
  Psychiatric pathologies             0.156       0.938       0.855       1.028
  Respiratory pathologies             \<0.001     1.446       1.317       1.588
  Rheumatological pathologies         \<0.001     0.824       0.749       0.907
  Urinary pathologies                 \<0.001     1\. 586     1.460       1.722
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###### 

Antibiotics available in the Colombian Health System categorized according to the AWaRe classification.

  AWaRe Classification   ATC Subgroup                                  Antimicrobials                                                                                                                                
  ---------------------- --------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------
  **Access**             J01A                                          Tetracyclines                                                                                                                                 Tetracyclin, doxycyclin, minocyclin, lymecyclin
  J01B                   Amphenicols                                   Chloramphenicol                                                                                                                               
  J01C                   Beta-lactam antibacterials---penicillins      Phenoximethyl penicillin V, penicillin G benzatin, amoxicillin, amoxicillin + clavulanic, ampicillin, ampicillin + sulbactam, dicloxacillin   
  J01D                   Other beta-lactam antibacterials              Cefalexin, cefradin, cefadroxil                                                                                                               
  J01E                   Sulfonamides and trimethoprim                 Trimethoprim + sulfamethoxazol                                                                                                                
  J01F                   Macrolides, lincosamides and streptogramins   Clindamycin                                                                                                                                   
  J01G                   Aminoglycoside antibacterials                 Gentamicin, amikacin, tobramycin                                                                                                              
  J01X                   Other antibacterials                          Nitrofurantoin                                                                                                                                
  **Watch**              J01D                                          Other beta-lactam antibacterials                                                                                                              Cefuroxime, ceftriaxone, cefpodoxime
  J01F                   Macrolides, lincosamides and streptogramins   Erythromycin, clarithromycin, azithromycin, spiramycin                                                                                        
  J01M                   Quinolone antibacterials                      Ciprofloxacin, norfloxacin, levofloxacin, moxifloxacin                                                                                        
  J01X                   Other antibacterials                          Vancomycin                                                                                                                                    
  **Reserve**            J01X                                          Other antibacterials                                                                                                                          Linezolid
  Fosfomycin                                                                                                                                                                                                         
  **Other**              A07A                                          Intestinal antiinfectives                                                                                                                     Rifaximin
